Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer

Tomasz M Beer; Nicholas Vogelzang; Jiřina Bartůňková; Kurt Miller; William Oh; Stephane Oudard; Hardev Pandha; A Oliver Sartor; Radek Špíšek; Timothy O Toole; Niels G Borgstein; Winald R Gerritsen

doi:10.1186/2051-1426-3-S2-P164

Article info

Poster Presentation

Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer

Free

Authors

Tomasz M Beer Oregon Health & Science University, OHSU Knight Cancer Institute Portland OR USA PubMed articles Google scholar articles
Nicholas Vogelzang US Oncology Research, Comprehensive Cancer Centers Las Vegas NV USA PubMed articles Google scholar articles
Jiřina Bartůňková University Hospital Motol, Prague, Czech Republic and SOTIO a.s. Prague Czech Republic PubMed articles Google scholar articles
Kurt Miller Charité University Medicine Berlin Berlin Germany PubMed articles Google scholar articles
William Oh Division of Hematology/Medical OncologyThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York NY USA PubMed articles Google scholar articles
Stephane Oudard Georges Pompidou European Hospital Paris France PubMed articles Google scholar articles
Hardev Pandha University of Surrey Guildford UK PubMed articles Google scholar articles
A Oliver Sartor Tulane Cancer Center New Orleans LA USA PubMed articles Google scholar articles
Radek Špíšek University Hospital Motol, Prague, Czech Republic and SOTIO a.s. Prague Czech Republic PubMed articles Google scholar articles
Timothy O Toole Sotio, LLC Boston MA USA PubMed articles Google scholar articles
Niels G Borgstein Sotio, LLC Boston MA USA PubMed articles Google scholar articles
Winald R Gerritsen Radboud University Nijmegen Medical Centre Nijmegen Netherlands PubMed articles Google scholar articles

Citation

Beer TM, Vogelzang N, Bartůňková J, et al

Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer

Journal for ImmunoTherapy of Cancer 2015;3:P164. doi: 10.1186/2051-1426-3-S2-P164

Publication history

First published November 4, 2015.

Online issue publication

March 11, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password